Drugs / Tetanus Toxoid peptide
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02960230 Background | Nov 2016 → Dec 2023 | diffuse midline glioma, H3 K27M-mutant | Sabine Mueller, MD, PhD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus Toxoid peptide | “K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide.” NCT02960230 ↗ |
| Modality | Peptide | “Tetanus Toxoid peptide” NCT02960230 ↗ |